# Acrivon Therapeutics, Inc.: overview ACRV · Nasdaq · CIK 1781174 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/acrv.md) · [Financials](/companies/acrv/financials.md) · [Filings](/companies/acrv/filings.md) · [Insiders](/companies/acrv/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.59)](/filings/0001193125-25-280215.md) | not reported | [(0.51)](/filings/0001193125-26-221634.md) | [(0.55)](/filings/0001193125-26-346819.md) | [(0.47)](/filings/0001193125-25-280215.md) | not reported | [(0.49)](/filings/0001193125-26-221634.md) | [(0.43)](/filings/0001193125-26-346819.md) | | Free cash flow | $m | [(18.3) d](/filings/0001193125-25-280215.md) | [(18.2) d](/filings/0001193125-26-115123.md) | [(19.6)](/filings/0001193125-26-221634.md) | [(17.1) d](/filings/0001193125-26-346819.md) | [(13.2) d](/filings/0001193125-25-280215.md) | [(15.5) d](/filings/0001193125-26-115123.md) | [(20.6)](/filings/0001193125-26-221634.md) | [(14.9) d](/filings/0001193125-26-346819.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(9.32)](/filings/0000950170-23-010331.md) | [(7.56)](/filings/0000950170-24-037618.md) | [(2.74)](/filings/0000950170-25-046056.md) | [(2.38)](/filings/0001193125-26-115123.md) | [(2.02)](/filings/0001193125-26-115123.md) | | Free cash flow | $m | [(14.2)](/filings/0000950170-23-010331.md) | [(32.3)](/filings/0000950170-24-037618.md) | [(43.9)](/filings/0000950170-25-046056.md) | [(68.4)](/filings/0001193125-26-115123.md) | [(65.3)](/filings/0001193125-26-115123.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/acrv/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-22 | [Miller Mary](/insiders/1841088.md) | Chief Legal Officer, Officer | Sale (S) | 513 | $1.84 | $943.92 | [Form 4](/filings/0000905148-26-004554.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $21.8m | 12,229,396 | | Added +3,888,888 | | [Sands Capital Alternatives, LLC](/funds/1846444.md) | 2026-06-30 | $4.1m | 2,289,271 | | Added +166,666 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.7m | 952,008 | | Added +229,973 | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $1.6m | 888,130 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.4m | 758,863 | | Added +423 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $1.1m | 641,498 | | Added +252,103 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $946.7k | 531,856 | | Reduced −28,580 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $674.4k | 378,900 | | Added +220,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $472.3k | 265,241 | | Added +28,850 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $425.6k | 239,112 | | Added +30,173 | ## Recent filings [All 346 filings](/companies/acrv/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 16:10 ET | [8-K](/filings/0001193125-26-346859.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-346859 | | 2026-08-12 | 16:05 ET | [10-Q](/filings/0001193125-26-346819.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346819 | | 2026-06-17 | 17:28 ET | [8-K](/filings/0001193125-26-274410.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-274410 | | 2026-05-13 | 16:12 ET | [10-Q](/filings/0001193125-26-221634.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221634 | | 2026-05-13 | 16:10 ET | [8-K](/filings/0001193125-26-221626.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-221626 | | 2026-04-30 | 08:30 ET | [DEF 14A](/filings/0001193125-26-194206.md) | Proxy statement, period 2026-06-17 | 0001193125-26-194206 | | 2026-04-23 | 16:29 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000116.md) | Ownership report, active investor, amended | 0001346824-26-000116 | | 2026-03-23 | 16:28 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000081.md) | Ownership report, active investor, amended | 0001346824-26-000081 | | 2026-03-19 | 07:21 ET | [8-K](/filings/0001193125-26-115139.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-115139 | | 2026-03-19 | 07:10 ET | [10-K](/filings/0001193125-26-115123.md) | Annual report, period 2025-12-31 | 0001193125-26-115123 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-115123.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1781174 - Tickers: ACRV - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:05 ET. No prices; not investment advice.